A vital, global collaboration to protect patients from the harm that medicines can cause.
The WHO Programme for International Drug Monitoring is a group of more than 150 countries that share the vision of safer and more effective use of medicines. They work nationally and collaborate internationally to monitor and identify the harm caused by medicines, to reduce the risks to patients and to establish worldwide pharmacovigilance standards and systems. UMC has been responsible for the technical and operational aspects of the programme since 1978.
The WHO programme was created in 1968 to ensure that evidence about harm to patients was collected from as many sources as possible. This would enable individual countries to be alerted to patterns of harm that were emerging across the world and which might not be evident from their local data alone.
Currently 142 countries are members of the WHO Programme for International Drug Monitoring. Another 29 associate member countries are in the early stages of establishing their pharmacovigilance systems in preparation for full membership.
For more information about individual members of the WHO programme click on the map
Dark blue: Full member. Light blue: Associate member. White: Non-member.
*This map is an approximation of actual country borders.
View the list of full members and associate members.
Download pharmacovigilance guidelines from selected countries.
Read more about the range of services available to member countries.
UMC was created in 1978 as the WHO Collaborating Centre for International Drug Monitoring. The work we do potentially affects everyone on earth, with our success in building a global family and culture of patient safety a story of positive, international cooperation.
In addition to UMC in Sweden there are three other WHO Collaborating Centres working in pharmacovigilance: the WHO Collaborating Centre for Strengthening Pharmacovigilance Practices, Morocco; the WHO Collaborating Centre for Drug Statistics Methodology, Norway; and the WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services, India.